Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Michael Silverman
Innate Immunotherapeutics
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- the Wesley-St. Andrew'S Research Institute
Brisbane, Queensland, Australia
- Parc Clinical Research
Adelaide, South Australia, Australia
- Nucleus Network - Centre for Clinical Studies
Melbourne, Victoria, Australia
- Western Australian Neuroscience Research Institute
Perth, Western Australia, Australia
- Neurodegenerative Disorders Research
West Perth, Western Australia, Australia
- Optimal Clinical Trials
Auckland, New Zealand
- P3 Research
Wellington, New Zealand
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Oct 2014
- Primary completion
- 31 May 2017
- Completion
- 30 Jun 2017
- Last update posted
- 14 Jul 2017
- Registered enrollment
- 93
- Registry id
- NCT02228213
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.